Home » Posts tagged with » Bayer
Bayer to acquire US gene therapy company Asklepios BioPharmaceutical in $4bn deal

Bayer to acquire US gene therapy company Asklepios BioPharmaceutical in $4bn deal

German pharma giant Bayer has agreed to acquire US clinical-stage gene therapy company Asklepios BioPharmaceutical in a deal worth up to $4 billion. The portfolio of Asklepios BioPharmaceutical features investigational pre-clinical and clinical stage candidates, which are being developed for the treatment of neuromuscular, cardiovascular, central nervous system, and metabolic diseases. Asklepios BioPharmaceutical was established […]

Bayer to acquire KaNDy Therapeutics to add menopause drug candidate

Bayer has agreed to acquire KaNDy Therapeutics, a UK clinical-stage biotech company, in a deal worth up to $900 million, in a move to grow its drug development pipeline in women’s healthcare. Through the acquisition, the German healthcare company gains access to NT-814, a non-hormonal, once-daily, oral neurokinin-1,3 receptor antagonist in developmen for the treatment […]

Continue reading …
Bayer gets Lampit FDA approval for Chagas disease in pediatric patients

Lampit FDA approval : Bayer has bagged approval for its antiprotozoal medication Lampit (nifurtimox) from the US Food and Drug Administration (FDA) for the treatment of Chagas disease in pediatric patients, from newly born to less than 18 years of age, weighing at least 2.5kg. Chagas disease is an infectious tropical disease caused by Trypanosoma […]

Continue reading …
Bayer completes sale of animal health business to Elanco

Bayer has wrapped up its previously announced $7.6 billion sale of its animal health business division to US-based Elanco Animal Health. The transaction, which was announced in August 2019, was closed after meeting the closing conditions, which includes regulatory approvals. Following the closing of the deal, Bayer has been paid $5.17 billion in cash after […]

Continue reading …
Bayer to divest animal health business to Elanco for $7.6bn

US-based veterinary pharmaceuticals producer Elanco Animal Health has agreed to acquire German drug giant Bayer’s animal health business for $7.6 billion, financed by a combination of 70% cash and 30% equity. The transaction, which enhances emerging market presence and strengthens cattle business, will strengthen Elanco’s Innovation, Portfolio, and Productivity (IPP) strategy, creating the second largest […]

Continue reading …
Bayer to fully acquire US cell therapy company BlueRock Therapeutics

Bayer acquisition of BlueRock Therapeutics : Bayer will take full ownership in US cell therapy company BlueRock Therapeutics for an enterprise value of up to $1 billion, as per the latest pharma acquisition news. Headquartered in Cambridge, BlueRock Therapeutics develops engineered cell therapies in the fields of neurology, cardiology, and immunology using its proprietary induced […]

Continue reading …
Bayer, Orion secures Darolutamide FDA approval for prostate cancer

Darolutamide FDA approval : German pharma giant Bayer and Finnish pharma company Orion have secured approval from the US Food and Drug Administration (FDA) for their non-steroidal androgen receptor inhibitor (ARi) Nubeqa (darolutamide) for the treatment of men having non-metastatic castration-resistant prostate cancer (nmCRPC). The FDA approval of darolutamide was driven on the findings of […]

Continue reading …
Lilly wraps up $8bn acquisition of Loxo Oncology

US pharma giant Eli Lilly and Company (Lilly) has wrapped up its previously announced $8 billion acquisition of Connecticut-based biopharma company Loxo Oncology. Announced in January 2019, Lilly acquisition of Loxo Oncology is expected to expand the scope of the pharma giant’s oncology portfolio into precision medicines owing to the addition of a marketed therapy […]

Continue reading …
New oral blood thinner rivaroxaban from Bayer and Jannsen shown to cut recurrence of life-threatening blood clots

Bayer and Janssen Pharmaceuticals have revealed that their jointly developed oral blood thinner Xarelto (rivaroxaban) had considerably brought down the risk of recurring formation of life-threatening blood clots in the vein as per the findings of their late-breaking study. Rivaroxaban Blood Thinner Clinical Trial This, they demonstrated in a blood thinner clinical trial dubbed EINSTEIN CHOICE. […]

Continue reading …